Patents by Inventor Wensheng Yu

Wensheng Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170217940
    Abstract: The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A?, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: December 15, 2014
    Publication date: August 3, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Joseph Kozlowski, Craig Coburn, Wensheng Yu, Ling Tong, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang, Tao Ji
  • Patent number: 9598440
    Abstract: The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: March 21, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: W. Michael Seganish, William T. McElroy, Stephanie Brumfield, R. Jason Herr, Larry Yet, Jinhai Yang, James P. Harding, III, Ginny Dai Ho, Deen Tulshian, Wensheng Yu, Michael K.C. Wong, Brian Lavey, Joseph A. Kozlowski
  • Patent number: 9555038
    Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: January 31, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wensheng Yu, Ling Tong, Joseph A. Kozlowski, Oleg Selyutin, Lei Chen, Jae-Hun Kim, Deyou Sha, Razia Rizvi, Bandarpalle Shankar
  • Patent number: 9481682
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: November 1, 2016
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Ronald M. Kim, Jian Liu, Xiaolei Gao, Sobhana Babu Boga, Deodialsingh Guiadeen, Joseph A. Kozlowski, Wensheng Yu, Rajan Anand, Younong Yu, Oleg B. Selyutin, Ying-Duo Gao, Hao Wu, Shilan Liu, Chundao Yang, Hongjian Wang
  • Publication number: 20160257697
    Abstract: Thiophene-substituted tetracyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2, R3, R4 and R5 are as defined herein. The compositions comprising at least one thiophene-substituted tetracyclic compound, and methods of using the thiophene-substituted tetracyclic compounds for treating or preventing HCV infection in a patient are also provided.
    Type: Application
    Filed: December 31, 2013
    Publication date: September 8, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Ling Tong, Wensheng Yu, Joseph A. Kozlowski, Lei Chen, Oleg Selyutin, Seong Heon Kim, Michael Dwyer, Bin Hu, Bin Zhong, Dahai Wang, Jinglai Hao, Changmao Shen, Zhixin Lei, Weijun Wang
  • Publication number: 20150335648
    Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: December 31, 2013
    Publication date: November 26, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Wensheng Yu, Ling Tong, Joseph A. Kozlowski, Oleg Selyutin, Lei Chen, Jae-Hun Kim, Deyou Sha, Razia Rizvi, Bandarpalle Shankar, Bin Hu, Bin Zhong, Dahai Wang, Jinglai Hao, Wei Wei, Tao Ji, Shuai Zan
  • Publication number: 20150299224
    Abstract: The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: October 3, 2013
    Publication date: October 22, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: W. MICHAEL SEGANISH, WILLIAM T. MCELROY, STEPHANIE BRUMFIELD, JASON R. HERR, LARRY YET, JINHAI YANG, JAMES P. HARDING, III, GINNY DAI HO, DEEN TULSHIAN, WENSHENG YU, MICHAEL K.C. WONG, BRIAN LAVEY, JOSEPH A. KOZLOWSKI
  • Publication number: 20140378416
    Abstract: The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: September 11, 2012
    Publication date: December 25, 2014
    Inventors: Michael P. Dwyer, Kartik M. Keertikar, Qingbei Zeng, Robert D. Mazzola, JR., Wensheng Yu, Haiqun Tang, Seong Heon Kim, Ling Tong, Stuart B. Rosenblum, Joseph A. Kozlowski, Anilkumar Gopinadhan Nair
  • Patent number: 8859529
    Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 14, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bandarpalle B. Shankar, Seong Heon Kim, Wensheng Yu, Ling Tong, Michael K. C. Wong, Brian J. Lavey, Joseph A. Kozlowski, Lei Chen, Razia K. Rizvi, Aneta Maria Kosinski, De-Yi Yang, Guowei Zhou, Kristen E. Rosner, Luke Fire, Judson E. Richard, Dansu Li
  • Publication number: 20140206681
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 24, 2014
    Inventors: RONALD M. KIM, Jian Liu, Xiaolei Gao, Sobhana Babu Boga, Deodialsingh Guiadeen, Joseph A. Kozlowski, Wensheng Yu, Rajan Anand, Younong Yu, Oleg B. Selyutin, Ying-Duo Gao, Hao Wu, Shilan Liu, Chundao Yang, Hongjian Wang
  • Patent number: 8609635
    Abstract: The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, M1, X1 and X2 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Silyl Compound, and methods of using the Fused Tricyclic Silyl Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: December 17, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anilkumar Gopinadhan Nair, Kartik M. Keertikar, Seong Heon Kim, Joseph A. Kozlowski, Stuart Rosenblum, Oleg B. Selyutin, Michael Wong, Wensheng Yu, Qingbei Zeng
  • Patent number: 8569336
    Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: October 29, 2013
    Inventors: Ling Tong, Brian J. Lavey, Bandarpalle B. Shankar, Seong Heon Kim, Wensheng Yu, Joseph A. Kozlowski, Michael K. C. Wong, Lei Chen, Guowei Zhou, Razia K. Rizvi, Robert Feltz, Aneta Maria Kosinski, De-Yi Yang, Chaoyang Dai, Luke Fire, Vinay Girijavallabhan, Dansu Li, Janeta Popovici-Muller, Judson E. Richard, Kristin E. Rosner, M. Arshad Siddiqui, Liping Yang
  • Patent number: 8541572
    Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: September 24, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph A. Kozlowski, Wensheng Yu, Michael K. C. Wong, Seong Heon Kim, Ling Tong, Brian J. Lavey, Bandarpalle B. Shankar, De-Yi Yang, Robert Feltz, Aneta Maria Kosinski, Guowei Zhou, Razia K. Rizvi, Chaoyang Dai, Luke Fire, Vinay Girijavallabhan, Dansu Li, Janeta Popovici-Muller, Judson E. Richard, Kristin E. Rosner, M. Arshad Siddiqui, Liping Yang
  • Patent number: 8450355
    Abstract: This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? combinations thereof.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: May 28, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael K. C. Wong, Wensheng Yu, Ling Tong, Brian J. Lavey, Bandarpalle B. Shankar, Joseph A. Kozlowski, Seong Heon Kim, Guowei Zhou, De-Yi Yang, Razia K. Rizvi, Lei Chen, Aneta Maria Kosinzki, Kristin E. Rosner, Luke Fire, Judson E. Richard, Dansu Li
  • Patent number: 8361959
    Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: January 29, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew Stamford, Michael W. Miller, Duane Eugene DeMong, William J. Greenlee, Joseph A. Kozlowski, Brian J. Lavey, Michael K. C. Wong, Wensheng Yu, Xing Dai, De-Yi Yang, Guowei Zhou
  • Publication number: 20130012434
    Abstract: The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Application
    Filed: March 22, 2011
    Publication date: January 10, 2013
    Inventors: Michael K. Wong, Brian J. Lavey, Wensheng Yu, Joseph A. Kozlowski, Duanc E. DeMong, Xing Dai, Andrew W. Stamford, Michael W. Miller, Guowei Zhou, De-Yi Yang, William J. Greenlee
  • Publication number: 20130012493
    Abstract: The present invention relates to compounds of the general formula (I): wherein ring A, ring B, G, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Application
    Filed: March 22, 2011
    Publication date: January 10, 2013
    Inventors: He Zhao, Ping Chen, Peishan Lin, Peng Dai, Jason Louis Davis, Duane E. DeMong, Michael W. Miller, Xing Dai, Michael K. Wong, Brian J. Lavey, Wensheng Yu, Guowei Zhou, Andrew W. Stamford, Joseph A. Kozlowski, William J. Greenlee
  • Patent number: 8178553
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: May 15, 2012
    Assignee: Schering Corporation
    Inventors: Brian J. Lavey, Joseph A. Kozlowski, Guowei Zhou, Ling Tong, Wensheng Yu, Michael K. C. Wong, Shankar B. Bandarpalle, Neng-Yang Shih, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Aneta Maria Kosinski, Seong-Heon Kim, De-Yi Yang, Razia K. Rizvi
  • Publication number: 20120015926
    Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Application
    Filed: November 9, 2009
    Publication date: January 19, 2012
    Inventors: Ling Tong, Brian J. Lavey, Bandarpalle B. Shankar, Seong Heon Kim, Wensheng Yu, Joseph A. Kozlowski, Michael K.C. Wong, Lei Chen, Guowei Zhou, Razia K. Rizvi, Robert Feltz, Aneta Maria Kosinski, De-Yi Yang, Chaoyang Dai, Luke Fire, Vinay Girijavallabhan, Dansu Li, Janeta Popovici-Muller, Judson E. Richard, Kristen E. Rosner, M. Arshad Siddiqui, Liping Yang
  • Publication number: 20120010181
    Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof.
    Type: Application
    Filed: November 9, 2009
    Publication date: January 12, 2012
    Inventors: Joseph A. Kozlowski, Wensheng Yu, Michael K.C. Wong, Seong Heon Kim, Ling Tong, Brian J. Lavey, Bandarpalle B. Shankar, De-Yi Yang, Robert Feltz, Aneta Maria Kosinski, Guowei Zhou, Razia K. Rizvi, Chaoyang Dai, Luke Fire, Vinay Girijavallabhan, Dansu Li, Janeta Popovici-Muller, Judson E. Richard, Kristen E. Rosner, M. Arshad Siddiqui, Liping Yang